Atorvastatin

Drug Profile

Atorvastatin

Alternative Names: Atorvastatin calcium; Cardyl; CI 981; Lipitor; Prevencor; Sortis; Tahor; Xarator 10; YM 548; Zarator

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer Astellas Pharma; Laboratorios Phoenix; Pfizer
  • Class Amides; Antihyperlipidaemics; Fatty acids; Fluorobenzenes; Heptanoic acids; Pyrroles; Small molecules
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders; Heart failure; Hypercholesterolaemia; Hyperlipoproteinaemia type IIa; Hyperlipoproteinaemia type III; Hypertriglyceridaemia; Low HDL cholesterol
  • Phase III Veno-occlusive disorders
  • Discontinued Alzheimer's disease; Neurological disorders

Most Recent Events

  • 01 Jan 2017 Pfizer and Boca Raton Regional Hospital completes a phase III trial in Veno-occlusive disorders in USA and Canada (NCT01528709)
  • 15 Mar 2016 Biomarkers information updated
  • 09 Oct 2015 No recent reports on development identified - Phase-II/III for Hyperlipoproteinaemia type IIa (In adolescents, In children) in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top